Browse Biopharmaceutics topic

Product development subtopic

Articles 1-68 out of 68 article(s) Title Author Type Date Words Neovacs Initiates a Phase II Clinical Trial of TNF Kinoid in Rheumatoid Arthritis Patients Failing TNF Monoclonal Antibody Therapy. Dec 8, 2009 450 Korea : Hospira and Celltrion agree to develop and market eight biogeneric products. Oct 9, 2009 233 United States : KYTHERA Biopharmaceuticals presents its two Phase 2 clinical study results. Clinical report Oct 3, 2009 259 KYTHERA Biopharmaceuticals Presents Positive Data From Two Phase 2 Studies With ATX-101. Clinical report Oct 2, 2009 744 KYTHERA Biopharmaceuticals Announces Presentation of Phase 2 Data on Novel Fat Reduction Drug at ASDS Meeting. Oct 1, 2009 158 KYTHERA Biopharmaceuticals Announces Presentation of Phase 2 Data on Novel Fat Reduction Drug at ASDS Meeting. Sep 30, 2009 158 Pancreatic and Colorectal Cancer Novel Antibody Developed from a Vaccine to Begin Phase I Trial. Sep 17, 2009 423 Morria Biopharmaceuticals Plc. Obtains Institutional Review Board Clearance to Conduct Phase II Study in Contact Dermatitis Patients Using MRX6, a Novel Topical Anti-Inflammatory Drug. Aug 25, 2009 334 Omnia Biologics and AparnaBio Sign Lentivirus Drug Development Agreement. Aug 18, 2009 232 Alder Biopharmaceuticals Presents Results From Phase 1 Trial of ALD518 in Advanced Cancer at American Society of Clinical Oncology Annual Meeting. Jun 1, 2009 486 KYTHERA Biopharmaceuticals Announces Positive Results from Two Phase 2 Studies with ATX-101 Demonstrating Reduction of Submental Fat. Clinical report Jan 6, 2009 489 Omrix Biopharmaceuticals Announces Patient Enrollment Will Resume In Fibrin Pad U.S. Phase II Clinical Trial In Mild to Moderate Bleeding. Oct 24, 2008 450 Omrix Biopharmaceuticals Provides Update On Fibrin Pad U.S. Phase II Clinical Trial In Mild to Moderate Bleeding. Oct 9, 2008 386 Omrix Biopharmaceuticals Announces Interim Analysis Indicating Superiority of Fibrin Pad Versus SURGICEL in Mild to Moderate Bleeding In U.S. Phase II Clinical Trial And Provides Update On Additional Fibrin Pad Clinical Trials. Oct 8, 2008 855 Omrix Biopharmaceuticals Completes Enrollment of Initial 90 Patients Needed to Conduct Interim Analysis in Fibrin Pad U.S. Phase II Clinical Trial. Clinical report Sep 22, 2008 666 Panacea Pharmaceuticals Announces Issuance of a United States Patent Covering Anti-HAAH Antibodies. Sep 1, 2008 844 Omrix Biopharmaceuticals Initiates Phase II Clinical Trial in Israel for Fibrin Pad Product Candidate. Jul 2, 2008 653 OMRIX Biopharmaceuticals Initiates Phase II Clinical Trial for Fibrin Patch Product Candidate. Mar 27, 2008 397 Accentia Biopharmaceuticals to Announce Top-Line SinuNase Phase 3 Clinical Trial Results Later Today. Mar 24, 2008 774 Accentia Biopharmaceuticals Announces Results on Primary Endpoint in Clinical Study of SinuNase Lavage. Clinical report Mar 24, 2008 1533 Progenics Initiates Phase 2 Clinical Trials for PRO 140, a Novel HIV Antibody Therapy. Jan 15, 2008 1444 MorphoSys and Novartis forge strategic alliance. Brief article Jan 1, 2008 267 Accentia Biopharmaceuticals Reports Fiscal 2007 Year-End Results; Pivotal Phase III Results Pending for SinuNase(TM) and BiovaxID(TM). Dec 28, 2007 1324 Accentia Biopharmaceuticals Reaffirms its Confidence in the Ongoing Unblinding of the BiovaxID(TM) Phase 3 Data Based on a Track Record of Eliciting an Immune Response in 80% of Patients. Clinical report Dec 21, 2007 1046 OMRIX Biopharmaceuticals Initiates Phase I/II Clinical Trial to Evaluate Safety and Initial Efficacy of Adhexil(TM) in Preventing and/or Reducing Post-Operative Adhesions in Patients Undergoing Gynecological Surgery. Oct 24, 2007 562 Accentia Biopharmaceuticals Announces Unblinding and Analysis of Fast Tracked Phase 3 Trial for BiovaxID. Oct 16, 2007 1184 OMRIX Biopharmaceuticals Announces Positive Phase I Results with Fibrin Patch. Oct 16, 2007 675 Accentia Biopharmaceuticals Announces Completion of Enrollment in Fast-Tracked Pivotal Phase 3 Clinical Trial of SinuNase for Chronic Sinusitis. Oct 8, 2007 1187 Kythera Biopharmaceuticals Initiates Phase II Study of Its Adipolytic Agent for Reduction of Submental Fat. Aug 28, 2007 533 Accentia Biopharmaceuticals Updates Interim Analysis of Blinded Clinical Results in the Fast-Tracked Pivotal Phase 3 Trial of SinuNase for the Treatment of Refractory Chronic Sinusitis. Aug 15, 2007 1320 Accentia Biopharmaceuticals Files Pre-Investigational New Drug (IND) Application with FDA for Pivotal Phase 3 Clinical Trial of Revimmune for Refractory Multiple Sclerosis. Jul 31, 2007 1818 RegeneRx Biopharmaceuticals, Inc. Updates Clinical Trials Program. Jul 31, 2007 1215 RegeneRx Biopharmaceuticals, Inc. to Provide Update on Clinical Trials Program. Jul 17, 2007 525 Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis. Clinical report Jun 28, 2007 991 OMRIX Biopharmaceuticals Completes Patient Enrollment in Fibrin Patch Phase 1 Clinical Trial. Jun 28, 2007 666 Kythera Biopharmaceuticals Completes Enrollment in Phase II Actinic Keratosis Trial. Clinical report Jun 26, 2007 403 There Are Currently More Than 400 Antibody Based Drugs in Development for the Treatment of Cancer. Jun 15, 2007 318 Accentia Biopharmaceuticals' Majority-Owned Subsidiary, Biovest, Receives Request From the Independent Data Monitoring Committee to Conduct Interim Analysis of Anti-Cancer Vaccine, BiovaxID. Jun 13, 2007 1366 RegeneRx Biopharmaceuticals, Inc. Reports 2006 Year-End Results. Financial report Apr 2, 2007 1121 OMRIX Biopharmaceuticals Commences Phase 1 Clinical Trial for Fibrin Patch. Dec 7, 2006 640 KaloBios Commences Clinical Trial of Novel Antibody Rheumatoid Arthritis Drug Candidate. Nov 9, 2006 405 Dr. Hynda Kleinman Joins RegeneRx Medical and Scientific Advisory Board. Nov 8, 2006 750 Accentia Biopharmaceuticals Commences Fast-Tracked Phase 3 Clinical Trial of SinuNase for the Treatment of Chronic Sinusitis. Nov 6, 2006 701 ALEXION ENROLLS ECULIZUMAB PHASE III SHEPHERD TRIAL. Nov 1, 2006 1191 Former Amgen Manufacturing Executive Joins Insmed. Oct 25, 2006 790 OMRIX Biopharmaceuticals Announces Positive Phase 3 Clinical Trial Results for Human Thrombin. Oct 16, 2006 1149 OMRIX Biopharmaceuticals Enters into a Cooperative Research and Development Agreement (CRADA) with the National Institute of Allergy and Infectious Diseases (NIAID) to Develop Antibody-Based Therapeutics for the Treatment of Influenza. Oct 9, 2006 662 OMRIX Biopharmaceuticals to Webcast Review of Thrombin Phase 3 Clinical Trial Results on October 16, 2006. Sep 28, 2006 607 Teva Pharmaceutical Industries Ltd. and Protalix Biotherapeutics Ltd. Announce a Collaboration Agreement for the Development of Two Biopharmaceuticals, Based on Protalix's Recombinant Plant Cell Expression Technology. Sep 26, 2006 765 OMRIX Biopharmaceuticals Announces U.S. Phase III Clinical Trial for Intravenous Immunoglobulin (IVIG) in Subjects with Primary Immune Deficiency Diseases. Aug 17, 2006 601 RegeneRx Receives $545,000 Grant from FDA; Funding for Clinical Development of TB4 for Epidermolysis Bullosa. Aug 9, 2006 979 FDA Gives Permission to Use Very Sensitive Molecular Evidence of Cancer in BiovaxID Pivotal Phase 3 Clinical Trial: Company Intends to Use Blood Test to File Application for Accelerated Approval. May 16, 2006 1105 FDA Grants Accentia Biopharmaceuticals, Inc.'s Majority-Owned Subsidiary Fast Track Status for BiovaxID(TM); Personalized Vaccine for Follicular Non-Hodgkin's Lymphoma Receives Fast Track Status from FDA. May 11, 2006 916 InNexus Biotechnology and Affimed Therapeutics AG to Collaborate; Will Use SuperAntibody Technology to Target Multiple Cancers. Apr 10, 2006 554 RegeneRx Updates Web Site. Apr 6, 2006 300 RegeneRx to Present at Biotechnology Industry Organization's 2006 Business Forum. Apr 3, 2006 394 Accentia Biopharmaceuticals Announces Financial Results For Fiscal Year 2005. Jan 5, 2006 1348 Adherex Receives FDA Orphan Drug Designation for Eniluracil in Liver Cancer: Designation Provides Up to Seven Years of Market Exclusivity Upon Regulatory Approval. Dec 21, 2005 850 RegeneRx Receives Key Patent in Hong Kong. Dec 20, 2005 574 GlycoFi and Merck & Co., Inc. Enter into Broad Strategic Alliance for Research and Development; Multi-Year Collaboration to Develop Merck Products on GlycoFi Platform. Dec 12, 2005 291 New Study Shows Emezine(R) Demonstrates More Efficient Absorption Versus Swallowed Form of Prochlorperazine. Dec 12, 2005 811 MethylGene Reports Encouraging Preliminary Clinical Results for MGCD0103 in Ongoing Hematologic Oncology Trial. Dec 8, 2005 844 Progenics Pharmaceuticals Initiates Clinical Trial of Viral-Entry Inhibitor PRO 140 in HIV-Infected Patients; Monoclonal Antibody Designed to Block HIV Infection of Immune System Cells. Dec 1, 2005 1461 Accentia Biopharmaceuticals Announces That Follow-up Data from the Phase II Clinical Trial of BiovaxID(TM) Will Be Presented at the Annual Meeting of the American Society for Hematology. Dec 1, 2005 826 Biovest International Announces that It Will Report New Follow-up Data from Its Phase 2 Clinical Trial of BiovaxID(TM) at the Annual Meeting of the American Society for Hematology. Dec 1, 2005 694 MethylGene Initiates Phase I/II Clinical Trial with MGCD0103 and Azacitidine in Patients with MDS and AML. Nov 14, 2005 782 Barr and PLIVA sign agreement to develop generic G-CSF. Mar 1, 2005 824 Pharmacopeia Forms Strategic Alliance With WuXi PharmaTech. Mar 1, 2003 379